The aim of the TRACE trial is the development of individualized medicine. T-cell immunity is one of the most individualized aspects of human physiology. Using adoptive transfer of mulitvirus-specific T cells will enable the patient to protect himself instead of receiving toxic antiviral chemotherapy. T-cell therapy is "help to help themselves".
European patient health will benefit through a safe, curative and innovative individualized treatment option, that has not been available for the majority of eligible patients in the past. Further the project will contribute evidence-based data on this treatment:
- reduced rate of CMV, EBV or AdV infections/reactivations
- reduced frequency of hospitalizations
- reduced medication intake